drugset / Trial / NCT02547727

Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults

NCT02547727

RandomizedParallel-groupOpen-labelTreatment

Summary

A four-site intradermal rabies booster vaccination in HIV - infected patients who have ever received primary rabies vaccination could improve their immune response to this kind of vaccine.

Timeline

Start
2016-02
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabies vaccine Vaccine 0.1 ml Intramuscular
Subject Rabies vaccine Vaccine 0.5 ml Intramuscular

Indications